Late Thursday, Taiho Oncology, Taiho Pharmaceutical, And Cullinan Oncology Launched Rezilient3 Phase 3 Trial Of Zipalertinib Plus Chemotherapy As Potential First-line Treatment For Non-Small Cell Lung Cancer Harboring EGFR Exon 20 Insertion Mutations
Benzinga Newsdesk - Aug 4, 2023, 4:20AM